The global acute intermittent porphyria (AIP) market is projected to experience substantial growth, driven by advancements in AI, digital health technologies, and patient-centric drug development. AI-powered tools are enabling personalized treatment strategies and improved outcomes, while telemedicine and remote monitoring are revolutionizing AIP care delivery. This market analysis explores key trends, regional profiles, and prominent players shaping the future of AIP treatment.